Does Rallies show Form 4 insider transactions for IKT?

Yes. Rallies tracks IKT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.

Is IKT research on Rallies investment advice?

No. Rallies provides research, data, and educational context for IKT. It does not provide personalized investment advice.

IKT (Inhibikase Therapeutics, Inc. Common Stock) Stock Analysis - Insider Trades

Inhibikase Therapeutics, Inc. Common Stock (IKT) is a publicly traded Healthcare sector company. As of May 21, 2026, IKT trades at $1.72 with a market cap of $212.57M and a P/E ratio of -3.80. IKT moved +7.64% today. Year to date, IKT is -16.42%; over the trailing twelve months it is -15.58%. Its 52-week range spans $1.13 to $4.20. Analyst consensus is strong buy with an average price target of $6.20. Rallies surfaces IKT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who is trading IKT stock inside the company?

Recent IKT insider activity includes Sands Capital Life Sciences Pulse Fund II, L.P. bought 2.07M, Bellini Roberto bought 1.46M, Kush Arvind bought 145.00K, and Munshi Amit bought 365.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.

IKT Key Metrics

Key financial metrics for IKT
Metric	Value
Price	$1.72
Market Cap	$212.57M
P/E Ratio	-3.80
EPS	$-0.43
Dividend Yield	0.00%
52-Week High	$4.20
52-Week Low	$1.13
Volume	0
Avg Volume	0
Revenue (TTM)	$3.72M
Net Income	$-50.96M
Gross Margin	0.00%

Recent IKT Insider Trades

Sands Capital Life Sciences Pulse Fund II, L.P. bought 2.07M (~$3.00M) on Nov 21, 2025.
Bellini Roberto bought 1.46M (~$2.00M) on Oct 21, 2024.
Kush Arvind bought 145.00K (~$198.65K) on Oct 21, 2024.
Munshi Amit bought 365.00K (~$500.05K) on Oct 21, 2024.

Latest IKT News

Inhibikase Reports $170.4M Cash, EMA FAST-EU Greenlight for Phase 3 in 16 Countries — May 12, 2026
Inhibikase Grants 685,718 Options at $1.68 with Ten-Year Term — Apr 3, 2026
Inhibikase Initiates Two-Part Phase 3 PAH Trial, Holds $178.8M Cash — Mar 26, 2026
Bank of America Sees 240% Upside for IKT on Infrastructure Financing Boom — Feb 22, 2026

IKT Analyst Consensus

5 analysts cover IKT: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $6.20.

Common questions about IKT

Who is trading IKT stock inside the company?: Recent IKT insider activity includes Sands Capital Life Sciences Pulse Fund II, L.P. bought 2.07M, Bellini Roberto bought 1.46M, Kush Arvind bought 145.00K, and Munshi Amit bought 365.00K. Rallies tracks insider transaction dates, shares, prices, and estimated values.
Does Rallies show Form 4 insider transactions for IKT?: Yes. Rallies tracks IKT insider trading and Form 4 activity, including executive purchases, executive sales, transaction dates, shares, and prices when available.
Is IKT research on Rallies investment advice?: No. Rallies provides research, data, and educational context for IKT. It does not provide personalized investment advice.